Standing out in the field of IgY Immunotechnology

  • Home
    Home A full collection of all the Research Archive entries.
  • Years
    Years Sort entries by year.
  • Tags
    Tags Displays a list of tags that have been used in the blog.
  • Archives
    Archives Contains a list of research entries that were created previously.

Highly sensitive detection of cancer antigen human epidermal growth factor receptor 2 using novel chicken egg yolk immunoglobulin.

Posted by on in 2015
  • Font size: Larger Smaller
  • Hits: 1775
  • Print

Sun Y1Yang Y2Wang L3Lv L3Zhu J3Han W1Wang E1Guo X1Zhen Y4. 2015. Biologicals. 43(3):165-70. doi: 10.1016/j.biologicals.2015.03.002. Epub 2015 Apr 1.

1College of Pharmacy, Dalian Medical University, Dalian, Liaoning Province, China.
2Clinical Medicine of Seven-Year-Program, Dalian Medical University, Dalian, Liaoning Province, China.
3The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, China.
4College of Pharmacy, Dalian Medical University, Dalian, Liaoning Province, China. Electronic address:


Human epidermal growth factor receptor 2 (HER2) is an important biomarker that plays a crucial role in therapeutic decision-making for breast cancer patients. Ensuring the accuracy and reproducibility of HER2 assays by enzyme-linked immunosorbent assay (ELISA), western blot and immunohistochemistry (IHC) requires high sensitive and specific antibodies. Immunoglobulin Y (IgY) is a kind of avian antibody usually isolated from chicken egg yolks. Generation and use of IgY is of increasing interest in a wide variety of applications within the life sciences. In this study, IgYantibodies against two different truncated proteins of the extracellular domain (ECD) of human HER2 were produced, their sensitivity and specificity were evaluated. Specific IgYs were produced by hens immunized with the ECD proteins of human HER2 in long-standing immunization response and were isolated from yolks with a purity of 90% by water dilution, salt precipitations and ultrafiltration. The anti-HER2 IgYs were analytically validated for specificity by ELISA, western blot, immunocytochemistry and IHC. The IgYs bound desired targets in cells and fixed tissues and showed high affinity to HER2. The results demonstrated the viability of detection of HER2 with IgYs and showed promise for the using of IgYs in strict clinical validation.

Copyright © 2015 The International Alliance for Biological Standardization. Published by Elsevier Ltd. All rights reserved.


Breast cancer; Detection; HER2; IHC; IgY

[PubMed - in proces
Last modified on